title: In search of a real "targeted" therapy for thyroid cancer.
abstract: Over the past 5 years, patients with progressive radioactive iodine-refractory thyroid cancer have responded to "targeted" multikinase inhibitors, which inhibit angiogenesis and not the tumor cell. Here, selumetinib targets the mitogen-activated protein kinase pathway in papillary thyroid carcinoma and shows limited single-agent activity in the patients with tumors that harbor the (V600E)BRAF mutation.
authors.affiliation: Departments of Medicine and Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19010, USA. brosem@mail.med.upenn.edu
authors.forename: Marcia S
authors.initials: MS
authors.lastname: Brose
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002277:Carcinoma; D002291:Carcinoma, Papillary; D005260:Female; D006801:Humans; D008297:Male; D010597:Pharmacogenetics; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: C517975:AZD 6244; D001562:Benzimidazoles